^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP63 rearrangement

    i
    Other names: TP63, Tumor protein 63, Keratinocyte transcription factor KET, Transformation-related protein 63, Tumor protein p73-like, KET, P63, P73H, P73L, TP73L, SHFM4, EEC3, OFC8, Amplified in squamous cell carcinoma, p40, p51
    Entrez ID:
    8626
    Related biomarkers:
    Expression
    9ms
    Acquisition of TP63 Rearrangement in Large Cell Transformation of Mycosis Fungoides. (PubMed, EJHaem)
    No abstract available
    Journal
    |
    TP63 (Tumor protein 63)
    |
    TP63 rearrangement
    1year
    Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan. (PubMed, Br J Dermatol)
    DUSP22 rearrangement is relatively specific to pcALCL among CD30+ CTCLs in Japan. Although the LEF1 expression pattern was not related to DUSP22 rearrangement in pcALCL, there was no rearrangement if LEF1 was not expressed. We confirmed that T3 stage and the lower limb involvement were significantly associated with decreased OS and DSS. The presence or absence of lower limb lesions should be included in T-stage subcategorization in the future.
    Retrospective data • Journal
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8) • TP63 (Tumor protein 63) • DUSP22 (Dual Specificity Phosphatase 22) • LEF1 (Lymphoid Enhancer Binding Factor 1) • USP22 (Ubiquitin Specific Peptidase 22)
    |
    TNFRSF8 expression • TP63 rearrangement